ALTU 237

Drug Profile

ALTU 237

Alternative Names: ALTU-237

Latest Information Update: 29 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altus Pharmaceuticals
  • Class Enzymes
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperoxaluria

Most Recent Events

  • 15 Jun 2009 Suspended - Phase-I for Hyperoxaluria in USA (PO)
  • 05 Jun 2008 Final safety data from a phase I trial in Hyperoxaluria released by Altus
  • 15 Aug 2007 Phase-I clinical trials in Hyperoxaluria in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top